CollPlant Biotechnologies Ltd. - Ordinary Shares (CLGN)

CLGN stock results show that CollPlant Biotechnologies beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

CLGN stock results show that CollPlant Biotechnologies met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

CLGN stock results show that CollPlant Biotechnologies missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

Companies Reporting Before The Bell • Conagra Brands (NYSE:CAG) is likely to report quarterly earnings at $0.65 per share on revenue of $3.01 billion.

Companies Reporting Before The Bell • CollPlant Biotechnologies (NASDAQ:CLGN) is likely to report quarterly loss at $0.13 per share on revenue of $3.50 million.

CollPlant Biotechnologies Ltd (NASDAQ: CLGN) shares are trading higher Monday after the company announced it achieved a milestone in its product collaboration agreement with AbbVie Inc (NYSE:

Gainers Benitec Biopharma Inc. (NASDAQ: BNTC) climbed 104% to $0.4050 after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy.

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Companies Reporting Before The Bell • Bank of Nova Scotia (NYSE:BNS) is estimated to report quarterly earnings at $1.78 per share on revenue of $8.09 billion.